Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactococcus lactis subsp. lactis LL-1
- Development stage
- Preclinical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactococcus lactis subsp. lactis LL-1 is a specific probiotic strain of lactic acid bacteria (LAB) being investigated for its potential in managing metabolic disorders, particularly obesity and hyperlipidemia. In preclinical studies using high-fat diet-induced obese mouse models, LL-1 has demonstrated the ability to significantly reduce body weight, blood lipid levels, and liver oxidative stress. Its mechanism of action involves the modulation of the gut microbiota, specifically by decreasing the Firmicutes-to-Bacteroidetes ratio to limit excess energy absorption and promoting the growth of beneficial taxa such as Muribaculaceae and Bacteroides. This microbial shift leads to an increase in short-chain fatty acid (SCFA) production and a reduction in gut pathogens. Furthermore, LL-1 enhances host antioxidant defenses by increasing the activity of enzymes like superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) while decreasing lipid peroxidation markers such as malondialdehyde (MDA).
- Other names
- L. lactis subsp. lactis LL-1Lactococcus lactis LL-1
Beyond the preview
Go deeper on Lactococcus lactis subsp. lactis LL-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactococcus lactis subsp. lactis LL-1.